- News and analysis
- Dividend Aristocrats: Johnson & Johnson
Dividend Aristocrats: Johnson & Johnson
Johnson & Johnson was founded in 1886, and since the last 60 years is constantly raising its dividends. The company has a truly diversified business with three major segments: Consumer health, Pharmaceutical, Medical Devices.
The recent Q2 2022 earnings report was impressive despite consumer market tightening. The revenue grew by 3% year-on-year to $24 billion, while the net free cash flows rose to $8.1 billion over the first half of 2022. Dividend and buybacks were at $5.8 billion and at $2.6 billion respectively. Consumer health segment rose by 3% year-on-year amid elevated demand for analgesics and upper airways medicine. Skin Care Neutrogena brand significantly contributed to the segment earnings. Pharmaceutical sales were up by 12% year-on-year mainly on rising cancer treatment medicine, Grohn’s disease drugs, precox treatment and some other diseases. The COVID-19 vaccine is not expected to make a significant contribution to the segment. Medical Devices segment was up by 3% year-on-year on elevated demand for surgical systems and electrophysiology equipment. Diversified business and vas cash flows are magnetizing investors worldwide, especially now as JNJ stock prices are 7% below the beginning of 2022.
The comments, insights, and reviews posted in this section are solely the opinions and perspectives of authors and do not represent the views or endorsements of RHC Investments or its administrators, except if explicitly indicated. RHC Investments provides a platform for users to share their thoughts on financial market news, investing strategies, and related topics. However, we do not guarantee the accuracy, completeness, or reliability of any user-generated content.
Investment Risks and Advice:
Please be aware that all investment decisions involve risks, and the information shared on metadoro.com should not be considered as financial advice. Always conduct thorough research, seek professional advice, and exercise caution when making investment decisions.
Moderation and Monitoring:
While we strive to maintain a respectful and informative environment, we cannot endorse or verify the accuracy of all user-generated content. We reserve the right to moderate, edit, or remove any comments or posts that violate our community guidelines, infringe on intellectual property rights, or contain harmful content.
By submitting content to metadoro.com, users grant RHC Investments a non-exclusive, royalty-free license to use, display, and distribute the content. Users are responsible for ensuring they have the necessary rights to share the content they post.
To maintain a positive and respectful community, users are expected to adhere to the community guidelines of Metadoro. Any content that is misleading, offensive, or violates applicable laws and regulations will be subject to moderation or removal.
Changes to Disclaimer:
We reserve the right to update, modify, or amend this disclaimer at any time. Users are encouraged to review this disclaimer periodically to stay informed about any changes.